The DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis
Open accessAbstract
In the majority of patients multiple sclerosis starts with a relapsing remitting disease (RRMS), which may at later times transform into secondary progressive disease (SPMS). In a minority of patients the relapsing remitting disease is skipped and the patients show progression from the onset (primary progressive MS, PPMS). Evidence obtained so far indicate major differences between RRMS and progressive MS, but no essential differences between SPMS and PPMS, with the exception of a lower incidence in the global load of focal white matter lesions and in particular in the presence of classical active plaques. We suggest that in MS patients two types of inflammation occur, which develop in parallel but partially independent from each other. The first is the focal bulk invasion of T- and B-lymphocytes with profound blood brain barrier leakage, which predominately affects the white matter and which gives rise to classical active demyelinated plaques. The other type of inflammation is a slow accumulation of T-cells and B-cells in the absence of major blood brain barrier damage in the connective tissue spaces of the brain, such as the meninges and the large perivascular Virchow Robin spaces, where they may form aggregates or in most severe cases structures in part resembling tertiary lymph follicles. This type of inflammation is associated with the formation of subpial demyelinated lesions in the cerebral and cerebellar cortex, with slow expansion of pre-existing lesions in the white matter and with diffuse neurodegeneration in the normal appearing white or grey matter. The first type of inflammation dominates in acute and relapsing MS. The second type of inflammation is already present in early stages of MS, but gradually increases with disease duration and patient age. CD8+ T-lymphocytes remain in the brain and spinal cord as tissue resident cells, which focally propagate neuroinflammation, when they re-encounter their cognate antigen. B-lymphocytes appear to propagate demyelination and neurodegeneration, most likely by producing soluble neurotoxic factors. Key open questions in MS research are the identification of the target antigen recognized by tissue resident CD8+ T-cells and B-cells and the molecular nature of the soluble inflammatory mediators, which trigger tissue damage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Multiple Sclerosis Phenotypic Classification
Lublin, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,259
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium 2 (2011) · Nature · doi:10.1038/nature10251 · Cited by 2,697
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905 · cited 11×
“These inflammatory sites mainly contain CD8+ T-cells, a major component of CD20+ B-cells and a variable number of plasma cells and may in their most severe manifestations become organized in structures with features of tertiary lymph follicles (green dots).”
BackgroundInfluentialCortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Self-citationMultiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724 · cited 1×
“In this situation PPMS could reflect the primary disease process of MS and the other courses (RRMS and SPMS) are those, modified by an inflammatory reaction (3).”
Backgroundvon Büdingen, H.-C., Palanichamy, A., Lehmann-Horn, K., Michel, B. A., & Zamvil, S. S. (2015) · European Neurology · doi:10.1159/000377675 · Cited by 1,463
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Frischer, J. M., Bramow, S., Dal-Bianco, A., Lucchinetti, C. F., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., & Lassmann, H. (2009) · Brain · doi:10.1093/brain/awp070 · Cited by 1,450
Self-citationMagliozzi, R., Howell, O., Vora, A., Serafini, B., Nicholas, R., Puopolo, M., Reynolds, R., & Aloisi, F. (2006) · Brain · doi:10.1093/brain/awm038 · Cited by 1,443
Cited by
Treatment of Multiple Sclerosis: A Review
Hauser, S. L., & Cree, B. A. C. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.05.049 · Cited by 969
B cell depletion therapies in autoimmune disease: advances and mechanistic insights
Lee, D. S. W., Rojas, O. L., & Gommerman, J. L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00092-2 · Cited by 658
de Almeida, L. G. N., Thode, H., Eslambolchi, Y., Chopra, S., Young, D., Gill, S., Devel, L., & Dufour, A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000349 · Cited by 535
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies
Faissner, S., Plemel, J. R., Gold, R., & Yong, V. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0035-2 · Cited by 459
Smouldering multiple sclerosis: the ‘real MS’
Giovannoni, G., Popescu, V., Wuerfel, J., Hellwig, K., Iacobaeus, E., Jensen, M. B., García-Domínguez, J. M., Sousa, L., De Rossi, N., Hupperts, R., et al. (2022) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211066751 · Cited by 271
Secondary Progressive Multiple Sclerosis: New Insights
Cree, B. A. C., Arnold, D. L., Chataway, J., Chitnis, T., Fox, R. J., Pozo Ramajo, A., Murphy, N., & Lassmann, H. (2021) · Neurology · doi:10.1212/wnl.0000000000012323 · Cited by 260
Self-citationBruton tyrosine kinase inhibitors for multiple sclerosis
Krämer, J., Bar-Or, A., Turner, T. J., & Wiendl, H. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00800-7 · Cited by 206
Mechanisms underlying progression in multiple sclerosis
Absinta, M., Lassmann, H., & Trapp, B. D. (2020) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000818 · Cited by 175
“Pathological changes in the brain and spinal cord are very similar in patients with primary and secondary progressive disease [24].”
BackgroundSelf-citationThe Emerging Role of Central and Peripheral Immune Systems in Neurodegenerative Diseases
Zang, X., Chen, S., Zhu, J., Ma, J., & Zhai, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.872134 · Cited by 139
Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis
Piehl, F. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13215 · Cited by 125
Cellular architecture of evolving neuroinflammatory lesions and multiple sclerosis pathology
Kukanja, P., Langseth, C. M., Rubio Rodríguez-Kirby, L. A., Agirre, E., Zheng, C., Raman, A., Yokota, C., Avenel, C., Tiklová, K., Guerreiro-Cacais, A. O., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.030 · Cited by 124
CD4 T Cells Induce A Subset of MHCII-Expressing Microglia that Attenuates Alzheimer Pathology
Mittal, K., Eremenko, E., Berner, O., Elyahu, Y., Strominger, I., Apelblat, D., Nemirovsky, A., Spiegel, I., & Monsonego, A. (2019) · iScience · doi:10.1016/j.isci.2019.05.039 · Cited by 114
“It cannot be excluded, though, that leukocytes such as CD8 T cells (Lassmann, 2018; Lassmann and Bradl, 2017), natural killer cells, and neutrophils (Cruz Hernandez et al., 2019) may also infiltrate the brain and cause neurotoxicity.”
BackgroundInhibition of CD40L with frexalimab in multiple sclerosis
Vermersch, P., Granziera, C., Mao-Draayer, Y., Cutter, G., Kalbus, O., Staikov, I., Dufek, M., Saubadu, S., Bejuit, R., Truffinet, P., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309439 · Cited by 102
Colombo, E., Bassani, C., De Angelis, A., Ruffini, F., Ottoboni, L., Comi, G., Martino, G., & Farina, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00635 · Cited by 66
“After several years of disease most of the RR-MS patients enter the progressive stage (called secondary progressive MS, SP-MS), characterized by steady accumulation of disability in absence of acute clinical events (4).”
BackgroundCollorone, S., Cawley, N., Grussu, F., Prados, F., Tona, F., Calvi, A., Kanber, B., Schneider, T., Kipp, L., Zhang, H., et al. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458519885107 · Cited by 64
Dysregulated copper transport in multiple sclerosis may cause demyelination via astrocytes
Colombo, E., Triolo, D., Bassani, C., Bedogni, F., Di Dario, M., Dina, G., Fredrickx, E., Fermo, I., Martinelli, V., Newcombe, J., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025804118 · Cited by 52
Geladaris, A., Torke, S., & Weber, M. S. (2022) · CNS Drugs · doi:10.1007/s40263-022-00951-z · Cited by 45
“Reactive astrogliosis is present in the NAWM and white and grey matter in MS patients, leading to continuous production of pro-inflammatory factors, ROS, and RNS [40].”
BackgroundInfluentialRelapsing and progressive MS: the sex-specific perspective
Rommer, P. S., Ellenberger, D., Hellwig, K., Haas, J., Pöhlau, D., Stahmann, A., Zettl, U. K., & on behalf of the Scientific Advisory Group of the German MS-Register by the German MS Society (2020) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286420956495 · Cited by 37
Chitinase Signature in the Plasticity of Neurodegenerative Diseases
Russo, C., Valle, M. S., Casabona, A., & Malaguarnera, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076301 · Cited by 29
Kihara, Y., Zhu, Y., Jonnalagadda, D., Romanow, W., Palmer, C., Siddoway, B., Rivera, R., Dutta, R., Trapp, B. D., & Chun, J. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.918041 · Cited by 26
Viral mouse models used to study multiple sclerosis: past and present
Libbey, J. E., & Fujinami, R. S. (2021) · Archives of Virology · doi:10.1007/s00705-021-04968-5 · Cited by 26
The role of the adaptive immune system in the initiation and persistence of multiple sclerosis
Afzali, A. M., & Korn, T. (2025) · Seminars in Immunology · doi:10.1016/j.smim.2025.101947 · Cited by 25
The Median Eminence, A New Oligodendrogenic Niche in the Adult Mouse Brain
Zilkha-Falb, R., Kaushansky, N., & Ben-Nun, A. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.04.005 · Cited by 19
McNally, J. S., Sakata, A., Alexander, M. D., Dewitt, L. D., Sonnen, J. A., Menacho, S. T., Stoddard, G. J., Kim, S.-E., & de Havenon, A. H. (2021) · American Journal of Neuroradiology · doi:10.3174/ajnr.a7047 · Cited by 18
“The traditional dichotomy of CAA with or without inflammation may instead represent a spectrum of proinflammatory cascades as with other neuroimmunologic diseases, including multiple sclerosis.(39) Without an overt link to inflammation on pathology, however, the use of novel immunotherapies in patients with CAA with V…”
BackgroundBuonvicino, D., Ranieri, G., Pratesi, S., Guasti, D., & Chiarugi, A. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113065 · Cited by 18
Brieva, L., Calles, C., Landete, L., & Oreja-Guevara, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1543649 · Cited by 16
Tong, L., Ozes, B., Moss, K., Myers, M., Attia, Z., Vetter, T. A., Trapp, B. D., & Sahenk, Z. (2025) · Gene Therapy · doi:10.1038/s41434-025-00518-9 · Cited by 8
Dagnew, B., Campbell, J. A., Laslett, L. L., Honan, C. A., Lefever, K., Taylor, B. V., Saul, A., & van der Mei, I. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106778 · Cited by 5
Lehto, J., Sucksdorff, M., Nylund, M., Raitanen, R., Matilainen, M., & Airas, L. (2023) · Journal of Neurology · doi:10.1007/s00415-022-11539-4 · Cited by 4
Metabolic control of microglia
Garcia-Segura, M. E., Pluchino, S., & Peruzzotti-Jametti, L. (2024) · Advances in Neurobiology · doi:10.1007/978-3-031-55529-9_34 · Cited by 4
Characterization of pathological stages in a mouse model of progressive multiple sclerosis
Hamano, S., Yoshimizu, T., Mori, M., Iida, A., & Yamashita, T. (2024) · Neuroscience Research · doi:10.1016/j.neures.2024.01.009 · Cited by 3
Metadata
- Authors
- Lassmann, H.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-01-10
- Volume
- 9
- Pages
- 3116-3116
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2909270098
- Cited by
- 663
- References
- 118
- FWCI
- 45.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.